Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells.
Sílvia Castro CoelhoDaniel Pires ReisMaria Carmo PereiraManuel A N CoelhoPublished in: Pharmaceutics (2018)
Colloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer cells. The nanoconjugates were designed by the bioconjugation of pegylated gold nanoparticles with varlitinib via carbodiimide-mediated cross-linking and characterized by infrared and X-ray photoelectron spectroscopy. The drug release response shows an initial delay and a complete drug release after 72 h is detected. In vitro experiments with MIA PaCa-2 cells corroborate that PEGAuNPsVarl conjugates increase the varlitinib toxic effect at very low concentrations (IC50 = 80 nM) if compared with varlitinib alone (IC50 = 259 nM). Our results acknowledge a decrease of drug side effects in normal cells and an enhancement of drug efficacy against to the pancreatic cancer cells reported.
Keyphrases
- gold nanoparticles
- drug release
- induced apoptosis
- drug delivery
- cell cycle arrest
- cancer therapy
- reduced graphene oxide
- high resolution
- photodynamic therapy
- small molecule
- single molecule
- endoplasmic reticulum stress
- magnetic resonance imaging
- oxidative stress
- cell proliferation
- cell death
- magnetic resonance
- pi k akt
- pluripotent stem cells
- nucleic acid